SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021
04 nov. 2021 16h05 HE
|
SIGA Technologies Inc.
- Up to Approximately $113 Million of Oral TPOXX® Targeted for Delivery to the U.S. Government in the Fourth Quarter - - Approximately $13 Million of International Sales for the First Nine Months of...
SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results
28 oct. 2021 16h15 HE
|
SIGA Technologies Inc.
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®
13 sept. 2021 07h30 HE
|
SIGA Technologies Inc.
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced the exercise of a procurement option under its...
SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021
07 sept. 2021 13h16 HE
|
SIGA Technologies Inc.
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that Dr. Phil Gomez, the Company’s Chief...
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021
05 août 2021 16h15 HE
|
SIGA Technologies Inc.
- Approximately $7 Million in International Sales of Oral TPOXX® in the Second Quarter – - Authorization of Additional $50 Million Share Repurchase Program - - Corporate Update Conference Call...
SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results
29 juil. 2021 16h15 HE
|
SIGA Technologies Inc.
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic
29 juil. 2021 03h30 HE
|
SIGA Technologies Inc.
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it...
SIGA Supplies TPOXX® (Tecovirimat) as Compassionate Treatment for Monkeypox Case in the United Kingdom
30 juin 2021 07h30 HE
|
SIGA Technologies Inc.
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it...
SIGA Reports Financial Results for Three Months Ended March 31, 2021
06 mai 2021 16h05 HE
|
SIGA Technologies Inc.
- Approximately $3 Million in International Sales of Oral TPOXX® in the First Quarter - - Approximately $7 Million in International Sales of Oral TPOXX® in April - - Corporate Update Conference...
SIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXX
04 mai 2021 07h30 HE
|
SIGA Technologies Inc.
NEW YORK, May 04, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has...